+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
S

Actively Recruiting

Researchers are evaluating AGN1 LOEP, a local osteo-enhancement procedure, to prevent secondary hip fractures in osteoporotic women who have already had an initial hip fracture and surgery. This randomized controlled trial involves postmenopausal women aged 65 to 91 years who experienced a low-energy fragility hip fracture. The study aims to reduce the chance of a second hip fracture by comparing the new treatment to standard care alone. Participants will be randomly assigned to one of two groups the treated group receives standard hip fracture repair plus the AGN1 LOEP procedure on the opposite unfractured hip, while the control group receives standard repair without the AGN1 LOEP treatment. The AGN1 LOEP procedure involves injecting implant material into the unfractured hip immediately after surgery. This study is single-blinded, except in Canada where it is not blinded. Participants will attend scheduled follow-up visits at 6 weeks, 6 months, and every 6 months thereafter for at least 5 years. During these visits, researchers will monitor for new hip fractures, adverse events, and measure bone mineral density at 12 and 24 months. The study will assess the cumulative incidence of secondary hip fractures and safety outcomes over time, with a minimum follow-up of 5 years after the initial hip repair surgery.

Age: 65Years - 91YearsFEMALEPhase Not Applicable
66 locations